Sunitinib (Sutent®) is a multikinase inhibitor of VEGFR 1–3, RET and PDGFRα/β, currently approved for the treatment of RCC, imatinib-resistant gastrointestinal stromal tumors (GIST) and pancreatic neuroendocrine tumors (pNET) [86–88]. Here, RET is linked to gastrointestinal stromal tumor.